Elinzanetant for endocrine therapy-related vasomotor symptoms in women with or at high risk for hormone receptor-positive breast cancer

Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Elinzanetant with Placebo (2 arms). Primary endpoints: Mean change in frequency of moderate to severe hot flash from baseline to Week 4 and Mean change in frequency of moderate to severe hot flash from baseline to Week 12. Planned start Feb 2024; status: authorised.